Huma

Healthcare was built for episodic, in-clinic treatment, yet its primary burden is now chronic and continuous: long-term conditions drive roughly 90% of health spending in developed markets. Built on a 1970s assumption, the prevailing model dictates that a patient walks in, is seen, and walks out, leaving the vast expanse of lived experience between visits as a dangerous blind spot. It is within this darkness that complications quietly escalate, ultimately returning individuals to the hospital at a far greater human and economic cost. Charting a course to proactive care has historically been stifled by systemic friction; every disease requires bespoke protocols, regulators rightly demand hard medical-device classifications, and pharmaceutical partners need deployments that scale across geographies. For decades, almost no digital-health solution could satisfy all three demands simultaneously.

We invest in companies that develop proprietary technological assets to shatter these exact bottlenecks. Huma’s answer is a foundational infrastructure platform that absorbs the immense regulatory cost of a medical device once, and amortizes it across hundreds of use cases. With generative AI embedded in their architecture, Huma has deployed AI agents that analyze doctor-patient conversations to automatically structure clinical notes and billing information, removing massive administrative friction from the system. By drastically lowering the barrier to build, the cost of launching a new, regulated disease pathway plummets from tens of millions of dollars to roughly $100,000, shrinking deployment timelines from years to mere weeks.

Every new clinical pathway built on the platform deepens Huma's regulatory moat and widens the catalogue buyers can draw on, turning a one-time clearance into a compounding advantage. This combined perspective of societal and market value has driven undeniable pull on both sides of the market, counting over 100 global clients across pharma, health systems, and governments. Health systems rely on Huma to manage patient populations at scale, while the pharmaceutical industry builds on the platform to run global trials and companion programs, highlighted by their joint venture with Wheel to deliver an integrated, direct-to-consumer virtual care platform. Each new deployment makes the next one faster to sign and cheaper to deliver, building the definitive digital infrastructure for a preferable future of continuous, proactive health.

We have followed digital health for years, wary of a category long on promise and short on clinical rigour. Huma stood out because it treats care delivery as an engineering problem: a single, disease-agnostic platform cleared across FDA, EU MDR and Saudi FDA, on which health systems and pharma can ship clinical-grade products in days. Dan Vahdat and Rich Khatib have spent over a decade proving that AI and regulatory depth can scale together.

As Founder and CEO, Dan Vahdat approached the complexities of healthcare by isolating a structural bottleneck: the millions of dollars and years of regulatory friction required to build a single medical application. He solved this by engineering Huma Cloud, a highly configurable, self-service platform that acts as a foundational enabler for the entire health ecosystem. By securing the highest levels of global regulatory clearance, Dan effectively eliminated the barrier to entry for health systems and startups globally, allowing them to build digital health products for a fraction of the historical cost. His engineering vision has propelled Huma to a $1 billion valuation, securing $355 million in total funding and earning recognition from the Financial Times as one of Europe's fastest-growing healthcare companies.

Raw technological capacity requires rigorous clinical translation to succeed in a hospital environment. Dr. Mert Aral, Huma’s Chief Medical Officer, embeds this complex architecture directly into the workflows of global health systems. He ensures that Huma’s AI-supported assessments and remote patient monitoring tools meet exact regulatory safety standards. Under his clinical direction, these digital tools effectively power "hospitals at home" that have been independently shown to almost double clinical capacity and reduce hospital readmissions by over a third. He translates digital biomarkers into personalized treatment plans, actively empowering patients while ensuring that true clinical utility drives every data science innovation.

Together, they have constructed a regulated, AI-driven engine that is actively transitioning global medicine to a proactive, continuous standard of care.

In May 2025, Huma acquired Aluna, a US-based respiratory remote monitoring company, adding over 150 US health systems and clinics to its platform. Alongside this acquisition, Huma announced a strategic M&A partnership with Eckuity Capital to accelerate further acquisitions in the digital health space.